Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  estrogen receptor
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

The ESR1 and GPX1 gene expression level in human malignant and non-malignant breast tissues

100%
Król M., Galicki M., Grešner P., Wieczorek E., Jabłońska E., Reszka E., Morawiec Z., Wąsowicz W., Gromadzińska J.
Acta Biochimica Polonica
|
2018
|
vol. 65
|
issue 1
51-57
EN
Background: The aim of this study was to establish whether the gene expression of estrogen receptor alpha (encoded by ESR1) correlates with the expression of glutathione peroxidase 1 (encoded by GPX1) in the tumor and adjacent tumor-free breast tissue, and whether this correlation is affected by breast cancer. Such relationships may give further insights into breast cancer pathology with respect to the status of estrogen receptor. Methods: We used the quantitative real-time PCR technique to analyze differences in the expression levels of the ESR1 and GPX1 genes in paired malignant and non-malignant tissues from breast cancer patients. Results: ESR1 and GPX1 expression levels were found to be significantly down-regulated by 14.7% and 7.4% (respectively) in the tumorous breast tissue when compared to the non-malignant one. Down-regulation of these genes was independent of the tumor histopathology classification and clinicopathological factors, while the ESR1 mRNA level was reduced with increasing tumor grade (G1: 103% vs. G2: 85.8% vs. G3: 84.5%; p<0.05). In the non-malignant and malignant breast tissues, the expression levels of ESR1 and GPX1 were significantly correlated with each other (Rs=0.450 and Rs=0.360; respectively). Conclusion: Our data suggest that down-regulation of ESR1 and GPX1 was independent of clinicopathological factors. Down-regulation of ESR1 gene expression was enhanced by the development of the disease. Moreover, GPX1 and ESR1 gene expression was interdependent in the malignant breast tissue and further work is needed to determine the mechanism underlying this relationship.
2
Content available remote

Two Different Primary Carcinomas in One Breast - Diagnostic and Therapeutic Challenge: A Case Report

75%
Jeziorski A., Kubiak R., Piekarski J.
Polish Journal of Surgery
|
2007
|
vol. 79
|
issue 7
508-511
EN
We present a case of 44-year old women with two primary carcinomas diagnosed in one breast. The carcinomas were invasive mixed ductal-lobular and lobular invasive carcinoma. This specific case was difficult to treat because these carcinomas are differentially susceptible to hormonal treatment. We refrained from making therapeutic decisions based solely on characteristics of the first primary would be improper because important therapeutic option (hormonal treatment) would not be used to treat the other primary. Therefore, the treatment would have been suboptimal. In our opinion, this case supports the close examination of biological characteristics of each carcinoma focus, especially if greater than one cancer focus with different morphology exists in the breast tissue.
3
Publication available in full text mode
Content available

Ciąża po raku piersi

63%
Skrzypczyk-Ostaszewicz A., Jagielska B., Śpiewankiewicz B., Maździarz A., Jaxa-Larecka D.
Current Gynecologic Oncology
|
2014
|
vol. 12
|
issue 1
25-30
EN
Many young patients having undergone radical treatment of breast cancer start considering motherhood at some point. The desire to become a mother may appear within a differing period from the completion of cancer therapy, yet it seems that regardless of the period, it is almost inevitably accompanied by major-level anxiety and stress. The decision about whether to become pregnant turns out a very difficult one, due to numerous doubts, uncertainties, and myths that have been commonly accepted concerning the safety of pregnancy for the future mother (i.e. the risk of cancer recurrence while pregnant), the effect of the undergone chemotherapy on the fetus, and breastfeeding-related issues. At the moment the disease is diagnosed, it is extremely rare for a young woman to immediately look out into her future in terms other than mere survival chances. The shock and the fear which are bound with the diagnosis hardly allow to ponder on the woman’s functioning following the treatment, or on her chances to return to all social roles. In some patients the fear of cancer recurrence and of the potential inability to raise the child themselves is so grave, it never allows them to make the decision to become mothers. Psycho-oncologic counseling, therefore, may have crucial impact over the choices made by breast cancer survivors, and not only should it be made available while patients are still tackling the diagnosis and treatment, but well beyond that period, throughout the healing process and follow-up monitoring time. The recent reports from the past few years seem to clarify many doubts and uncertainties, and this paper brings together the most important results of the new research available.
PL
Wiele młodych pacjentek po radykalnym leczeniu raka piersi zaczyna w pewnym momencie rozważać macierzyństwo. Chęć urodzenia dziecka pojawia się w różnym czasie po zakończeniu leczenia, ale wydaje się, że niezależnie od tego okresu niemal zawsze pociąga za sobą lęk i stres. Decyzja o ciąży okazuje się bardzo trudna – wynika to z licznych niejasności i pokutujących mitów dotyczących bezpieczeństwa ciąży dla przyszłej matki (czyli ryzyka nawrotu choroby), wpływu przebytej przez nią chemioterapii na płód i kwestii związanych z karmieniem piersią. W chwili rozpoznania choroby nowotworowej młoda kobieta bardzo rzadko od razu podejmuje temat swojej przyszłości w kontekście innym niż przeżycie. Szok i strach, bezsprzecznie towarzyszące diagnozie, zwykle nie pozwalają na rozważania o przyszłym funkcjonowaniu kobiety po leczeniu i powrocie do wszystkich ról społecznych. U części pacjentek lęk przed wznową raka i ewentualną niemożnością wychowania dziecka jest tak nasilony, że nigdy nie decydują się na macierzyństwo. Poradnictwo psychoonkologiczne może mieć zatem znaczący wpływ na wybory dokonywane przez kobiety po zakończeniu leczenia raka piersi – powinno być dostępne nie tylko podczas zmagania się z diagnozą i leczeniem, lecz także długo później, w okresie zdrowienia i obserwacji po terapii. Doniesienia z kilku ostatnich lat rozwiewają wiele wątpliwości, a niniejsza praca stanowi podsumowanie najważniejszych wyników nowych badań.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.